Why do the largest U.S. drugmakers owe no U.S. corporate income tax?
Core argument: The top six U.S. pharmaceutical companies by revenue set aside zero — less than zero, as several report tax losses — out of their 2024 profit for U.S. corporate income tax, with only Eli Lilly provisioning roughly $1 billion.
Most of the major U.S. pharmaceutical companies (AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Johnson and Johnson, Merck, and Pfizer) have reported the amount they have set aside out of their 2024 profit to pay their U.S. corporate income tax bill. That number—when the provisions of the top six U.S. companies by revenue is summed—is zero. Less than zero, actually—as several companies report tax losses. Only Eli Lilly actually set aside a significant sum (roughly $1 billion) for its tax payments to the U.S. Treasury. It is a direct function of keeping intellectual property offshore, investing to produce valuable patent protected drugs offshore, and booking the profit on U.S. sales offshore. In other words, it’s the predictable result of the tax and production structures that most large U.S. pharmaceutical companies have adopted following the 2017 Tax Cut and Jobs Act. The lack of tax payments in the U.S. should not be a surprise. The typical large U.S. pharmaceutical company reports losing money on their U.S. operations. Lots of money apparently.

